PDCD1 and hepatocellular carcinoma: In addition, HCC patients refractory to frontline treatments are treated with ramucirumab, targeting vascular endothelial growth factor (VEGF) receptor-2, or the immune checkpoint inhibitor nivolumab, targeting programmed cell death 1 (PD-1).